UNSPSC 51172337: Linaclotide

An oligo-peptide agonist of guanylate cyclase 2C. It was approved by the FDA in August 2012 and by the European Medicines Agency[4] for the treatment in adults of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

UNSPSC 51172337 Linaclotide is a Commodity code that maps to pharmaceutical procurement, but the recent state and local activity under this code does not reflect pharmaceutical purchases. Instead, Collin County Community Supervision and Corrections Department posted RFP 2026-327 for offender specimen collection and drug testing services — a scope entirely outside the nominal drug-product category. The work involves staffing two physical collection sites in Plano and McKinney for randomized urinalysis and alternative testing (oral fluid, hair), operating an Interactive Voice Response system for test notifications, conducting immunoassay screening with laboratory confirmation (LC/MS/MS or GC/MS), and delivering electronic result reporting. Annual testing volume is approximately 25,031 tests across five-panel, six-panel, and ancillary assays. The successful vendor must maintain SAMHSA, Texas DPS, or CAP laboratory certification. Pricing is per-test with three service models (screening only, confirmation after screening, screening with automatic confirmation of positives), and all costs including staffing, freight, and delivery must be embedded in the per-test rate with no additional surcharges allowed. The estimated contract value is $600,000 over two years with three optional one-year renewal periods.

The code shows minimal relevant recent activity; the single posted opportunity reflects a classification mismatch rather than pharmaceutical procurement activity typical of this Commodity code. Collin County Community Supervision and Corrections Department is the issuing body, and the RFP 2026-327 closed July 23, 2026, with award anticipated August 10, 2026. Evaluation criteria emphasize vendor understanding and firm qualifications (55 combined points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews worth up to 30 additional points. Contract funding derives from Texas Department of Criminal Justice-Community Justice Assistance Division appropriations subject to annual availability, and price redetermination is limited to September 1 anniversaries with increases capped at 3.0 percent annually based on medical Consumer Price Index. Business development professionals should verify whether this code is the correct classification vehicle for pharmaceutical solicitations in their target markets before committing pursuit resources.